anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham EA intervention and combined with placebo took orally. The follow-up period is 6 months.
FIELD: cosmetics industry. SUBSTANCE: this can be used in the form of evening creams for skin care and also in the form of cosmetic masks. Cosmetic means has base in the form of gel and biologically-active substances and additives. Used in function of biologically-active substance is natural or recombined protein alpha-fetoprotein, and used in function of biologically-active additives are components of natural and chemical origin. Proportioning of base and biologically-active substances is (0.8-5.8):1.0 and their quantitative ratio is as follows, mas.%: protein alpha-fetoprotein natural or recombined 10 -5 -10 -4 , base and biologically-active additives of natural or chemical origin in proportion of (0.8-5.8):1.0, the balance up to 100%. Used in function of base is gel of polyethyleneoxide. This cosmetic preparation allows for using highly active protein alpha-fetoprotein thus widening of spectrum of biologically-active substances used in cosmetic activities. EFFECT: higher efficiency. 2 cl, 10 ex
PURPOSE: A pharmaceutical composition comprising the extract of a seed of Carthamus tinctorius L. is provided, for promoting the generation of hard tissues such as bones and teeth. CONSTITUTION: The pharmaceutical composition comprises the extract of a seed of Carthamus tinctorius L. The extract of a seed of Carthamus tinctorius L. is prepared by repeating the procedure consisting of heating the 50-100% methanolic aqueous solution containing a seed of Carthamus tinctorius L. at a temperature of 50-120°C for 5-24 hours, cooling the solution to 40-60°C, and filtering the solution; and concentrating the solution. The extract of a seed of Carthamus tinctorius L. is also prepared by repeating the procedure consisting of leaving the 50-100% methanolic aqueous solution containing a seed of Carthamus tinctorius L. at room temperature or at 4°C for 5-7 days, filtering the solution; and concentrating the solution. The extraction liquid is dried to obtain a powder. The composition comprises the extract of a seed of Carthamus tinctorius L. in the forms of a liquid or a powder. The composition promotes the proliferation of osteoblast and periodontal ligament cell and increases the activity of alkali phosphatase, thereby promotes the regeneration and proliferation of hard tissues, therefore can be used for treating or preventing osteoporosis or periodontitis. The composition can be used in the form of a toothpaste or a gargle. Also the composition can be used as an additive of the feed for a hatcher to strengthen the shell of an egg.
PROBLEM TO BE SOLVED: To obtain a dermatitis-preventing agent safe for human bodies, thermally not deactivated, soluble in water, wide in application range and exhibiting excellent dermatitis-preventing and treating effects by including highly pure sericin extracted from cocoons or raw silks as an active ingredient. SOLUTION: Sericin contained in cocoons or raw silks is extracted with water, or hydrolyzed with an acid, an alkali or an enzyme and subsequently extracted. The extract is mixed with a water-soluble organic solvent such as methanol to deposit the sericin. The deposited sericin is filtered out and subsequently dried to obtain the sericin powder, or the deposited sericin is subjected to an ultrafiltration treatment or a reverse osmosis treatment and subsequently dried to obtain the sericin powder. The amount of the sericin to be added to a dermatitis-preventing agent is especially not limited, if expressing the effect, but is preferably e.g. 0.1-50wt.% based on the whole preparation.
Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (100 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
FIELD: biochemical pharmacology. SUBSTANCE: invention relates to selenium-containing protein organic substances with immunocorrecting properties. Substances include low-molecular component - protein, selenium, carbohydrate residues, phospholipid and cyanide anions. Invention can be used in medicine for treatment of patients with diseases associated with inhibition of production of cells CD4-helpers and increase of population of cells CD8-suppressors. EFFECT: recovery of index of immunoregulation. 5 cl, 6 dwg, 5 ex
The present invention relates to the application of crust oligosaccharide sulfuric ester and/or chitosan sulfuric ester to the preparation of a medicine for reducing blood sugar. The compounds of the medicine for preventing and treating diabetes comprise crust oligosaccharide sulfuric ester (CSA) and/or chitosan sulfuric ester (CSB). the typical structures of the two compounds are shown by the right formula, wherein the n is polymerization degree which is from 3 to 600; the R1 is SO3Na or H; the R2 is SO3Na or H or Ac; both the R1 and the R2 are H except for Ac. the content of the active group, namely sulfuric ester base (OSO3<->) of the compound is from 40.73 to 42.21%, wherein the molecular weight of the crust oligosaccharide sulfuric ester (CSA) in a yellowish cotton state is from 1 to 6KD; the molecular weight of the chitosan sulfuric ester (CSB) in a yellowish cotton stage is from 30 to 100KD. The medicine compound displays activity on the aspects of resisting blood sugar, adjusting blood fat, reinforcing immunity, resisting blood coagulation, etc., and is influenced by the sulfuric ester base, which is an active group and the molecular weight thereof. The preparation method belongs to homogeneous reaction. The present invention has the advantages of simpleness, low operation cost, little pollution and high raw material utilization rate.
The research coordinator will set up a time for the subject to have a brief discussion with a peer coach from the study team approximately 1 week after randomization. During the coaching session, the peer coach will encourage the subject to mention their heart health goals to their primary care clinician during their next primary care appointment. The peer coach will also help the subject brainstorm ways to remove any barriers that may prevent them from having the discussion with their clinician. The peer coaching session and the subsequent medical appointment will be audio-recorded.
An Internet based method for assisting in the rapid delivery of medical information direct to the site at which emergency assistance is being performed uses a global database for warehousing patient history information, which is fetched over the Internet on demand. In one embodiment, medical providers use an access code carried by the injured party and without which access is denied. The access code may be carried as a barcode and as an imprinted number on a bracelet or on a card carried by the individual. Patient information is transmitted over a network, either wireline or wireless, the Internet or wide area network, to a computer or personal digital assistant available to emergency personnel. In one embodiment, patient history information access is determined through the use of an access code reader, by entering the patient access code manually or by entering the patient's name as a last resort. Additionally insurance information can be made available to shorten emergency room admission procedures. 
     Lastly, the patient's card or bracelet can allow for patient history to be downloaded and saved. Thus in emergency situations, the information can be uploaded from the card or bracelet to the healthcare providers' viewing screens.
The primary aim of the present study was to present a case series of 24 patients with foveal triangular fibrocartilage complex (TFCC) injuries that were treated with arthroscopically assisted TFCC foveal repair. In total, 19 patients had a stable distal radioulnar joint (DRUJ) and five had an unstable DRUJ. Despite this, all patients were found to have a foveal tear upon DRUJ arthroscopy. Magnetic resonance imaging (MRI) scans detected only eight out of 23 patients with foveal injuries. In addition to their foveal injury, 19 of the 24 patients had additional pathology that required treatment. At a mean follow-up of 18 months, there was a statistically significant improvement in pain, range of motion, grip strength and functional scores. In this study, we demonstrate that having a stable DRUJ upon clinical examination and normal MRI findings does not rule out foveal TFCC injury and a high index of clinical suspicion is needed when managing patients with ulnar sided wrist pain.Level of evidence: IV.
<P>PROBLEM TO BE SOLVED: To prevent an oversight of a disease by a doctor and to improving the diagnostic efficiency.  <P>SOLUTION: Image data inputted by an image data input means 11 are stored in an image memory means 12. Next, the image data are read and analyzed, and an abnormal shadow candidate is detected by an abnormal shadow candidate detecting means 13 to prepare abnormal shadow candidate information. Next, the order of displaying images is determined by an image output selecting means 21 based on the malignancy, contrast, and degree of difficulty in diagnosis of the abnormal shadow candidate part, and patient information or the imaged section. Then, the image data are displayed in an image display means 22 according to the determined order of displaying images. The abnormal shadow candidate information is screen displayed by an abnormal information visual transmission means 23, or audibly outputted by an abnormal information sound transmission means 24, or transmitted both in the visual display and in the sound output.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Patients will recieve 12 sessions (2x/week) of standard of care exercise-based physiotherapy with implementation of cognitive dual task training. This implies that the patients will perform cognitive tasks simultaneously during at least 50% of their physical rehabilitative exercises.
The patient should be treated stable during the observation period with a novel anticoagulant (at least one prescription per half-year). This means that no vitamin-k-antagonists prescriptions and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year from the start of the observation period.
The quadratus lumborum transmuscular block will be performed immediately at the end of the surgery. Administration of 0.4 mL of 0.25% bupivacaine will be carried out under ultrasound guidance and performed by experienced anesthesiologists.
Participants will take part in a 12-hour educational discussion-based mentoring program intervention over 8 weeks. The intervention will be facilitated by a trained father facilitator and will include education and support on topics relevant to perinatal fathers. Topics include father identity, stress management, infant development, co-parenting, masculinity and caregiving, healthy communication, and work-life balance. Participants will additionally have access to a brief educational podcast series on related topics. Participants will also be invited to monthly follow-up daddy/baby drop-in groups.
BACKGROUND: Laparoscopic Total Extra-peritoneal Inguinal Hernia Repair(TEP) presents escalated risks of surgical complications, notably bleeding, particularly in European Hernia Society (EHS) types 3 and recurrent inguinal hernia. In this study, we introduced an innovative technique using indocyanine green-labeled fluorescence laparoscopy to mitigate intraoperative complications, including bleeding and rupture of the hernial sac.
METHODS: This retrospective study reviewed records of 17 patients who underwent TEP repair at Anqing Municipal Hospital between July and August 2023. Intraoperatively, fluorescence imaging was utilized to trace the pathway of the spermatic vessels and outline the boundaries of the hernia sac to facilitate a thorough dissection.
RESULTS: The procedure was successfully completed in all 17 patients, with a median operation time of 42 min (range: 30-51 min). Median intraoperative blood loss was 5 ml (range: 3-8 ml). Complete dissection of the hernia sac was achieved in each case without any incidents of sac rupture. Hemodynamic parameters of blood flow within the spermatic artery on postoperative day 1 showed no statistically significant deviations from the preoperative values. Furthermore, during the 7-month follow-up period, there were no cases of seroma formation or hernia recurrence.
CONCLUSION: Our findings suggest that employing indocyanine green-labeled fluorescence technology in TEP repair significantly reduces intraoperative complications, notably bleeding and rupture of the hernial sac. This technique demonstrated a negligible impact on the hemodynamic parameters of the spermatic artery and reduced the overall surgical time.
This study is the second phase of work in Zambezi and Ohangwena Regions, Namibia, building off a formative phase of work that characterized the risk behaviors migratory patterns, health-seeking behaviors, intervention strategies and social networks of agricultural workers and cattle herders, who are previously identified malaria high-risk populations (HRPs). This phase of the study now aims to determine the effectiveness, cost-effectiveness, acceptability, and feasibility of targeted delivery of a package of malaria interventions for improving effective coverage and reducing Plasmodium falciparum malaria transmission in these regions among these populations.

The study will specifically assess the coverage and impact of interventions delivered at worksites to HRPs, including presumptive treatment administered alongside vector control interventions (indoor residual spraying \[IRS\], long-lasting insecticidal nets \[LLINs\], and topical repellents). The effectiveness of these interventions will be compared against areas with no study interventions (standard of care) over the course of implementation (November 2019 - May 2020). Primary outcomes will include the coverage of each intervention at worksites over the study period and PCR-based P. falciparum prevalence measured at endline. Following a baseline cross-sectional survey in November/December 2019, the interventions will consist of 2 rounds of presumptive treatment spaced at least one month apart between January and March, and delivery of vector control interventions at worksites and key access points with support from employers, with the primary evaluation to be conducted through an endline cross-sectional survey in April/May 2020. Secondary outcomes around effectiveness will be assessed through incident case data providing measures of incidence in HRP and non-HRP populations, odds of infection associated with each intervention in cases compared to controls and entomological data collection. In addition, operational and feasibility outcomes will be assessed through qualitative data collection, population size estimation of HRP groups and a global positioning system (GPS) logger study.
PURPOSE: A method for proliferating stem cells is provided to transform stem cells to c-MET gene and to activate c-MET/HGF signal transduction system. CONSTITUTION: A stem cells has induced c-MET gene and a gene encoding HGF. The c-MET gene contains a nucleic acid of sequence number 1. The stem cell is neural stem cells or neural crest stem cells derived from the human adult brain. The brain is the temporal lobe or hippocampus. The gene transduction is performed by mediating a virus vector. The virus is retro virus, adeno virus, herpesvirus, epstein-Barr virus, or lentivirus. A cell therapeutic agent for treating neural diseases contains the stem cells.
After consent and study enrollment the subject will be scheduled for CT simulation for radiation treatment planning. At the time of CT simulation, they will be immobilized by means of a thermoplastic mask. For patients in the control arm, the radiation treatment planning will proceed as normal. Treatment planning is performed on Pinnacle. The patient will return for validation of the radiation plan. Validation involves collecting on-table X-rays or cone beam CTs when the patient is in position for treatment, which is the standard of care. Most often, the date of validation will happen within 5 business days of the CT simulation.
A stable liquid pharmaceutical composition for oral administration comprising (a) topiramate, or its pharmaceutically acceptable salts thereof, present in a range of 0.05% w/v to 5% w/v, (b) a mixture of at least two solubilizers, and (c) a non-aqueous solvent, is provided. Preferably, the non-aqueous solvent is selected from the group consisting of glycerol, isopropyl myristate, isopropyl palmitate, almond oil, olive oil, isopropyl alcohol or a combination thereof. Preferably, the mixture of at least two solubilizers is selected from the group consisting of propylene glycol, polyethylene glycol, polysorbates, ethanol, polyhydric alcohol, poloxamer, or combination thereof, and wherein the non-aqueous solvent is glycerol. The liquid pharmaceutical composition may further comprise a sweetener and a flavouring agent. A process for the preparation of the stable liquid pharmaceutical composition is also provided. A composition comprising 1) 5mg/ml or 10mg/ml topiramate; 2) a mixture of solubilizers selected from propylene glycol, polyethylene glycol 400, polysorbate 80 and ethanol having a total concentration of 0.1mg/ml to 100mg/ml; 3) 0.8mg/ml sodium saccharin; 4) glycerol; and 5) 0.65mg/ml levomenthol is outlined.
Aminophylline Injection, USP is a sterile, nonpyrogenic solution of aminophylline in water for injection. Aminophylline (dihydrate) is approximately 79% of anhydrous theophylline by weight. Aminophylline Injection is administered by slow intravenous injection or diluted and administered by intravenous infusion.

The solution contains no bacteriostat or antimicrobial agent and is intended for use only as a single-dose injection. When smaller doses are required the unused portion should be discarded.

Aminophylline is a 2:1 complex of theophylline and ethylenediamine. Theophylline is structurally classified as a methylxanthine. Aminophylline occurs as a white or slightly yellowish granule or powder, with a slight ammoniacal odor. Aminophylline has the chemical name 1H-Purine-2, 6-dione, 3,7-dihydro-1,3-dimethyl-, compound with 1,2-ethanediamine (2:1). The structural formula of aminophylline (dihydrate) is as follows:

The molecular formula of aminophylline dihydrate is C16H24N10O4 • 2(H2O) with a molecular weight of 456.46.

Aminophylline Injection, USP contains aminophylline (calculated as the dihydrate) 25 mg/mL (equivalent to 19.7 mg/mL anhydrous theophylline) prepared with the aid of ethylenediamine. The solution may contain an excess of ethylenediamine for pH adjustment. pH is 8.8 (8.6 to 9.0). The osmolar concentration is 0.17 mOsmol/mL (calc.).
Continuous EEG recordings will be made using Ag/AgCl electrodes placed on or beneath the scalp (subdermal wire) according to standard practice. The default montage will employ eight lead electrodes for each hemisphere following the 10/20 system (Right: Fp2, F4, C4, P4, O2, F8, T4, T6; left: Fp1, F3, C3, P3, O1, F7, T3, T5). Other montages with more dense placement of electrodes in the region of ECoG monitoring may also be used.
Oral anticoagulation is the key to reduce the risk of stroke in atrial fibrillation. Although vitaminK antagonists (VKA) have classically been used for this purpose, they have been largely overcome by direct oral anticoagulants (DOAC), as demonstrated by evidence from clinical trials, real-life and population studies. In fact, all clinical practice guidelines recommend their use preferentially over VKA. However, in Spain the prescription of DOAC is subordinated to an inspection visa that includes the clinical conditions defined in the Therapeutic Positioning Report of the Spanish Medicines Agency, and that still imposes important restrictions on their use, limiting the benefits of using DOACs in patients with atrial fibrillation (AF), and also generating inequalities between the different autonomous communities. In fact, the use of DOAC in Spain is much lower than that observed in neighboring countries. This has made that while in other countries the incidence of ischemic stroke has decreased at the population level, along with a reduction in the cost per patient with AF, in Spain this decrease has been modest. For all these reasons, and for assuring the sustainability of the health care system, we ask for the elimination of the visa so that DOAC can be prescribed according to the recommendations made by the guidelines. In addition, we are also committed to reinforce medical education and decisions made by consensus with the patient, with the primary care physician acquiring a key role in the protection of the patient with AF.
Hematopoietic toxicity can occur following overdose, manifested by a decrease in the white cell count and/or platelets. Red blood cell count is a less accurate indicator of thiotepa toxicity. Bleeding manifestations may develop. The patient may become more vulnerable to infection, and less able to combat such infection. 

Dosages within and minimally above the recommended therapeutic doses have been associated with potentially life-threatening hematopoietic toxicity. Thiotepa has a toxic effect on the hematopoietic system that is dose related. 

Thiotepa is dialyzable. 

There is no known antidote for overdosage with thiotepa. Transfusions of whole blood or platelets have proven beneficial to the patient in combating hematopoietic toxicity.